Genome&Company Logo

Genome&Company

Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.

314130 | KO

Overview

Corporate Details

ISIN(s):
KR7314130006
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 7층, 8층, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genome & Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's core research and development programs are centered on microbiome-based pharmaceuticals, novel immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). Its primary therapeutic area is immuno-oncology, aiming to develop new treatments for various cancers. Genome & Company utilizes its proprietary drug discovery platform to advance its pipeline through clinical trials and strategic partnerships, including the out-licensing of its drug candidates to global pharmaceutical firms.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 00:00
M&A Activity
주요사항보고서(타법인주식및출자증권양도결정)
Korean 20.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.4 KB
2025-08-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.3 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 77.8 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 68.8 KB
2025-07-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 80.9 KB
2025-07-10 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-07-02 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 186.7 KB
2025-07-02 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 177.1 KB
2025-06-04 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 95.9 KB
2025-05-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.6 KB

Automate Your Workflow. Get a real-time feed of all Genome&Company filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genome&Company

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genome&Company via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea
216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea
007370
JOHNSON & JOHNSON Logo
Develops innovative medicines and medical technologies for complex diseases and personalized care.
United States of America
JNJ
Journey Medical Corp Logo
A pharmaceutical firm commercializing prescription drugs and generics for dermatology.
United States of America
DERM
JUPITER NEUROSCIENCES, INC. Logo
Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.
United States of America
JUNS
JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel
KDST
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556

Talk to a Data Expert

Have a question? We'll get back to you promptly.